Inspired by the role
of cell-surface glycoproteins as coreceptors
for pathogens, we report the development of
GlycoGrip
: a glycopolymer-based lateral flow assay for detecting SARS-CoV-2
and its variants.
GlycoGrip
utilizes glycopolymers
for primary capture and antispike antibodies labeled with gold nanoparticles
for signal-generating detection. A lock-step integration between experiment
and computation has enabled efficient optimization of
GlycoGrip
test strips which can selectively, sensitively, and rapidly detect
SARS-CoV-2 and its variants in biofluids. Employing the power of the
glycocalyx in a diagnostic assay has distinct advantages over conventional
immunoassays as glycopolymers can bind to antigens in a multivalent
capacity and are highly adaptable for mutated strains. As new variants
of SARS-CoV-2 are identified,
GlycoGrip
will serve
as a highly reconfigurable biosensor for their detection. Additionally,
via extensive ensemble-based docking simulations which incorporate
protein and glycan motion, we have elucidated important clues as to
how heparan sulfate and other glycocalyx components may bind the spike
glycoprotein during SARS-CoV-2 host-cell infection.
GlycoGrip
is a promising and generalizable alternative to costly, labor-intensive
RT-PCR, and we envision it will be broadly useful, including for rural
or low-income populations that are historically undertested and under-reported
in infection statistics.